Related Experiment Video

Updated: Mar 30, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

6.3K

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus

Curtis Triplitt1, Susan Cornell2

  • 1Texas Diabetes Institute, University Health System, San Antonio, TX, USA. ; Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Clinical Medicine Insights. Endocrinology and Diabetes
|November 3, 2015
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like canagliflozin, offer type 2 diabetes mellitus (T2DM) patients reduced A1C, weight, and blood pressure with low hypoglycemia risk. This review details canagliflozin

Area of Science:

  • Pharmacology and Therapeutics
  • Endocrinology
  • Metabolic Diseases

Background:

  • Current type 2 diabetes mellitus (T2DM) management emphasizes a patient-centered approach beyond glycemic control.
  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of antihyperglycemic agents with demonstrated benefits.
  • Clinical pharmacists play a vital role in multidisciplinary diabetes care teams.

Purpose of the Study:

  • To review the pharmacology, mechanism of action, and clinical benefits of the SGLT2 inhibitor canagliflozin.
  • To elucidate potential drug-drug interactions and safety considerations for canagliflozin use in T2DM.
  • To enhance clinical pharmacists' understanding and application of canagliflozin in T2DM patient care.

Main Methods:

  • Literature review of pharmacological data and clinical trial outcomes for canagliflozin.
  • Analysis of efficacy in reducing glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP).
  • Assessment of safety profile, including hypoglycemia risk and potential drug interactions.

Main Results:

  • Canagliflozin effectively reduces A1C, BW, and SBP in patients with T2DM.
  • SGLT2 inhibitors, including canagliflozin, are associated with a low risk of hypoglycemia.
  • Comprehensive understanding of canagliflozin's benefits and risks supports its role in T2DM management.

Conclusions:

  • Canagliflozin offers significant therapeutic advantages for T2DM management beyond glycemic control.
  • The drug's safety profile and low hypoglycemia risk make it a valuable option for patient-centered care.
  • Pharmacists can leverage this information to optimize canagliflozin therapy and improve patient outcomes.
Keywords:
SGLT2 inhibitorscanagliflozintreatment goalstype 2 diabetes

More Related Videos

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

1.0K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
931
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
938
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K